A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The general aim of this study is to determine if 3 MIU of IFN-α5 in monotherapy, and 1,5 MIU of IFN-α5 combined with 1,5 MIU of IFN- α2b, are safe dose levels as well as to investigate the antiviral efficacy and pharmacodynamics (PD) of such doses and drugs in treatment-experienced HCV patients with genotype 1 chronic infection, after 29 days of treatment. It is also intended to determine pharmacokinetics (PK) of the safe dose achieved of IFN-α5 in monotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

NCT00759200

Chronic Hepatitis C

COMPLETED PHASE2

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

NCT01185860

Hepatitis C, Chronic

COMPLETED PHASE1

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

NCT01508130

Hepatitis C, Chronic

COMPLETED

Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

NCT00686517

Hepatitis C

COMPLETED PHASE3

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

NCT00593151

Hepatitis C

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis C Virus Infection Genotype 1 Treatment-Experienced Patients Relapses

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interferon α-5

Group Type EXPERIMENTAL

Interferon α-5

Intervention Type DRUG

3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.

Interferon α-5 plus Interferon α-2b

Group Type EXPERIMENTAL

Interferon-α5 plus Interferon-α 2b

Intervention Type DRUG

Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.

Interferon α-2b (INTRON® A)

Group Type ACTIVE_COMPARATOR

Interferon α-2b (INTRON® A)

Intervention Type DRUG

3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interferon α-5

3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.

Intervention Type DRUG

Interferon-α5 plus Interferon-α 2b

Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.

Intervention Type DRUG

Interferon α-2b (INTRON® A)

3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged ≥18 years old,
2. With chronic hepatitis C (CHC) infection diagnosed by seropositivity for anti-HCV antibodies or detectable HCV-RNA, at least 6 months prior to screening.
3. Patients with CHC infection of genotype 1 (1a, 1b or mixed 1a/1b)
4. Defined as relapsers: those CHC patients who had achieved virologic response (HCV-RNA non detectable) at any time during the standard care of treatment for CHC with IFN-α2 or PegIFN-α2 + ribavirin, and maintained it trough the end of treatment at week 48 weeks, but HCV-RNA detection occurs before 6 months post-treatment.
5. In whom liver cirrhosis has been ruled out through fibro-scan or liver biopsy within 24 months prior to study enrolment.
6. With a serum HCV viral load ≥ 100.000 IU/mL at screening
7. With alanine-aminotransferase (ALT) and aspartate-aminotransferase (AST) serum measurements at screening less than 5 times of their upper limits of normal (ULN)
8. With a body mass index (BMI) of at least 18 kg/m2, but not exceeding 36 kg/m2.
9. For female subjects with childbearing potential: use of a known highly effective method of birth control
10. For male subjects with partners of child bearing potential: use of appropriate contraceptive methods.
11. Is able to effectively communicate with the investigator and other testing center personnel.
12. Is able to participate and willing to give written informed consent and comply with the study restrictions.

Exclusion Criteria

1. Hepatitis C infection of genotype 2, 3 or 4 or any mixed genotype (1/2, 1/3 and 1/4).
2. A positive ELISA for HIV-1 or HIV-2.
3. Hepatitis B virus (HBV) infection based on the presence of HBsAg.
4. Hepatitis A virus (HAV) infection based on the presence of antiHAV-IgM. (AM 4)Criteria deleted
5. Decompensated liver disease, or history of decompensated liver disease.
6. History or other evidence of a medical condition associated with decompensated renal, immunologically mediated, chronic pulmonary, cardiac, thyroid, severe retinopathy, severe psychiatric, organ transplantation, cancer, seizure disorder or pancreatitis diseases.
7. An active or suspected malignancy or history of malignancy within the last five years.
8. Patients with a documented drug and alcohol addiction free history of at least 12 months who are, in the opinion of the investigator unlikely to relapse, may be enrolled in the study.
10. Haemoglobin \<12.0g/dL for women, and \<13.0g/dL for men at screening.
11. White blood cell count \<2000 cells/mm3 at screening.
12. Absolute neutrophil count \<1500 cells/mm3 at screening.
13. Platelet count \<100.000 cells/mm3 at screening.
14. ALT and AST levels ≥ 5 xULN at screening.
15. Prothrombin time INR prolonged to 1.5xULN at screening.
16. TSH an T4 outside normal limits and not adequately controlled thyroid function at screening.
17. Poorly controlled diabetes mellitus as evidenced by HbA1c \>7.5% at screening.
18. Alfa-fetoprotein value \>100ng/mL at screening.
19. Total bilirubin \>1.5xULN with ratio of direct/indirect \>1, at screening unless predominantly conjugated and reflecting Gilbert's disease
20. Estimated creatinine clearance of 30 mL/minute or less at screening.
21. Women who are confirmed to be pregnant
22. People with known hypersensitivity to any ingredient of the investigational agents
23. Patients who are at risk of bleeding.
24. Haemoglobinopathy
25. Screening ECG QTc value ≥ 450ms and/or clinically significant ECG findings.
26. History of clinically significant drug allergies.
27. Participation in a clinical study with an investigational drug, biologic, or device within 3 months prior to anticipated dose administration.
28. Any chronic viral (including HSV), bacterial, mycobacterial, fungal, parasitic, or protozoal infection.
29. Requirement for chronic systemic corticosteroids.
30. Receiving systemic antivirals, hematopoietic growth factor, or immunomodulatory treatment within 30 days prior to enrollment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No